Neogen’s (NASDAQ:NEOG) Q3 CY2026: Strong Sales, Stock Soars
Neogen (NEOG) reported Q3 CY2026 revenue of $222.8M, beating estimates by 7% and growing 6.5% YoY. Adjusted EPS of $0.08 beat estimates by 50%. The company raised full-year revenue guidance to $887.5M and EBITDA guidance to $182M, both above analyst estimates. Operating margin improved to -0.8% from -7.7% YoY, and free cash flow turned positive at $4.7M.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift are likely to attract short‑term buying, especially from traders focused on small‑cap biotech earnings.
Market read
Earnings surprise and guidance raise provide a fresh catalyst for NEOG, offering a trading opportunity in the near term.
What to watch
Potential headwinds from regulatory approvals and competitive pressures are not addressed in the release.
Background
Neogen reported Q3 2026 results, surpassing analyst expectations and modestly raising its full‑year outlook.
Ticker impact
Q3 2026 results beat estimates on revenue, EPS and EBITDA, and the company raised full-year guidance.
likely upward pressure as the market prices in the beat and higher guidance
The company posted a 6.5% YoY revenue increase, EPS beat by 50%, and lifted guidance, which typically drives buying interest.
Market effects
Strong performance may lift sentiment in the animal health and diagnostics sector.
Minimal regional impact; primarily affects U.S. biotech investors.
Limited to investors tracking small‑cap biotech earnings.
Counterpoint
The beat may be priced in quickly, and the modest revenue scale could limit upside.
Key entities
- companyNeogen
U.S. listed animal health and diagnostics company (NASDAQ:NEOG).
